學門類別
哈佛
- General Management
- Marketing
- Entrepreneurship
- International Business
- Accounting
- Finance
- Operations Management
- Strategy
- Human Resource Management
- Social Enterprise
- Business Ethics
- Organizational Behavior
- Information Technology
- Negotiation
- Business & Government Relations
- Service Management
- Sales
- Economics
- Teaching & the Case Method
最新個案
- A practical guide to SEC ï¬nancial reporting and disclosures for successful regulatory crowdfunding
- Quality shareholders versus transient investors: The alarming case of product recalls
- The Health Equity Accelerator at Boston Medical Center
- Monosha Biotech: Growth Challenges of a Social Enterprise Brand
- Assessing the Value of Unifying and De-duplicating Customer Data, Spreadsheet Supplement
- Building an AI First Snack Company: A Hands-on Generative AI Exercise, Data Supplement
- Building an AI First Snack Company: A Hands-on Generative AI Exercise
- Board Director Dilemmas: The Tradeoffs of Board Selection
- Barbie: Reviving a Cultural Icon at Mattel (Abridged)
- Happiness Capital: A Hundred-Year-Old Family Business's Quest to Create Happiness
Responsible Lobbying?
內容大綱
In 2006 Merck received FDA approval for Gardasil, the first vaccine for human papilloma virus (HPV) which had been identified as the cause of cervical cancer. Merck priced the vaccine at $360 for the three injections and was working on programs for the use of Gardasil in developing countries at much lower prices. Projected sales of Gardasil were $1 billion a year and billions more if states mandated vaccination. Prior to FDA approval, Merck began to develop a market for Gardasil and launched an intensive campaign to get states to make HPV vaccination of girls entering middle school mandatory. As the public and organized private groups became aware of Merck's efforts, however, the campaign generated a backlash against mandatory vaccination. Merck subsequently suspended its campaign and reflected on the experience in deciding its next moves.